Dolby Laboratories (NYSE:DLB – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Friday. A number of other ...

Rosenblatt Securities reiterated their buy rating on shares of Dolby Laboratories (NYSE:DLB – Free Report) in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a ...

Dolby Laboratories (DLB) has disclosed a new risk, in the Corporate Activity and Growth category. Dolby Laboratories faces significant business ...

Dolby Laboratories, Inc. ( NYSE:DLB ) investors will be delighted, with the company turning in some strong numbers ...

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...

Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14 ...

CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

Dolby Laboratories Inc (DLB) reports a 13% revenue increase, fueled by robust licensing performance and expanding automotive partnerships.

Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up ...

A new study published in Alzheimer’s & Dementia highlights a significant step forward in diagnosing Dementia with Lewy Bodies ...